Nuo Therapeutics, Inc.

AURX

US67059V2097

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:51:14 2024-05-15 am EDT			5-day change	1st Jan Change
0.75 ^USD	0.00%		-6.25%	+36.36%

Apr. 19	Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Exor-backed NUO invests in Italian teenage clothing chain Subdued	RE

Nuo Therapeutics, Inc. has withdrawn its IPO in the amount of $11.55 million.

August 04, 2017 at 12:00 am EDT

Nuo Therapeutics, Inc. has withdrawn its IPO in the amount of $11.55 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,100,000 PriceRange: $4.5 to $5.5

Latest news about Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 19	CI
Exor-backed NUO invests in Italian teenage clothing chain Subdued	Mar. 19	RE
Nuo Therapeutics, Inc. announced that it has received $0.9625 million in funding	Dec. 18	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.9625 million in funding	Dec. 07	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Insider Buy: Nuo Therapeutics	23-08-04	MT
Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding	23-07-31	CI
Nuo Therapeutics, Inc. announced that it expects to receive $1.035 million in funding	23-07-25	CI
Nuo Therapeutics Selects to Exhibit AurixÂ® System At Vizient Innovative Technology Exchange	23-06-26	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding from Pacific Medical, Inc.	22-08-23	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Nuo Therapeutics, Inc. Enters into an Exclusive Sales Agent and Services Agreement with Pacific Medical, Inc	22-06-28	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Insider Buy: Nuo Therapeutics	22-05-02	MT
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Nuo Therapeutics, Inc. announced that it expects to receive $3.55 million in funding	22-04-10	CI
Nuo Therapeutics, Inc. Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services	21-04-20	CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	20-01-31	CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding	19-11-14	CI

Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUO THERAPEUTICS, INC.	+36.36%	33.18M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs